Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review

Systemic sclerosis (scleroderma, SSc) is an autoimmune connective tissue disease characterized by excessive production of collagen and multiorgan involvement. Scleroderma patients are at increased risk of influenza complications and pneumonia; thus, vaccinations are recommended. This systematic revi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Francesca Rosamilia, Giovanni Noberasco, Dario Olobardi, Andrea Orsi, Giancarlo Icardi, Francesca Lantieri, Giuseppe Murdaca
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	systemic sclerosis scleroderma coverage pneumonia influenza systematic review Medicine R
Acceso en línea:	https://doaj.org/article/e2670fc22abf44579f4378de197154a5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e2670fc22abf44579f4378de197154a5
record_format	dspace
spelling	oai:doaj.org-article:e2670fc22abf44579f4378de197154a52021-11-25T19:11:22ZFlu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review10.3390/vaccines91113302076-393Xhttps://doaj.org/article/e2670fc22abf44579f4378de197154a52021-11-01T00:00:00Zhttps://www.mdpi.com/2076-393X/9/11/1330https://doaj.org/toc/2076-393XSystemic sclerosis (scleroderma, SSc) is an autoimmune connective tissue disease characterized by excessive production of collagen and multiorgan involvement. Scleroderma patients are at increased risk of influenza complications and pneumonia; thus, vaccinations are recommended. This systematic review evaluated the influenza and pneumococcus vaccination coverage for SSc patients. We included all studies from Pubmed reporting on influenza and pneumococcal vaccination rate in Scleroderma patients up to May 2021. The 14 studies thus selected identified a suboptimal vaccination rate in autoimmune and SSc patients, ranging from 28 to 59% for the flu vaccine, and from 11 to 58% for the pneumo vaccine in absence of specific vaccination campaigns, variously considering also other variables such as age, gender, vaccination settings, and possible vaccination campaigns. We also considered the reasons for low coverage and the approaches that might increase the vaccination rates. A lack of knowledge about the importance of vaccination in these patients and their doctors underlined the need to increase the awareness for vaccination in this patients’ category. Current guidelines recommend vaccination in elderly people and people affected by particular conditions that widely overlap with SSc, yet autoimmune diseases are not always clearly mentioned. Improving this suboptimal vaccination rate with clear guidelines is crucial for SSc patients and for clinicians to immunize these categories based principally on the pathology, prior to the age. Recommendations by the immunologist and the direct link to the vaccine providers can highly improve the vaccine coverage.Francesca RosamiliaGiovanni NoberascoDario OlobardiAndrea OrsiGiancarlo IcardiFrancesca LantieriGiuseppe MurdacaMDPI AGarticlesystemic sclerosissclerodermacoveragepneumoniainfluenzasystematic reviewMedicineRENVaccines, Vol 9, Iss 1330, p 1330 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	systemic sclerosis scleroderma coverage pneumonia influenza systematic review Medicine R
spellingShingle	systemic sclerosis scleroderma coverage pneumonia influenza systematic review Medicine R Francesca Rosamilia Giovanni Noberasco Dario Olobardi Andrea Orsi Giancarlo Icardi Francesca Lantieri Giuseppe Murdaca Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review
description	Systemic sclerosis (scleroderma, SSc) is an autoimmune connective tissue disease characterized by excessive production of collagen and multiorgan involvement. Scleroderma patients are at increased risk of influenza complications and pneumonia; thus, vaccinations are recommended. This systematic review evaluated the influenza and pneumococcus vaccination coverage for SSc patients. We included all studies from Pubmed reporting on influenza and pneumococcal vaccination rate in Scleroderma patients up to May 2021. The 14 studies thus selected identified a suboptimal vaccination rate in autoimmune and SSc patients, ranging from 28 to 59% for the flu vaccine, and from 11 to 58% for the pneumo vaccine in absence of specific vaccination campaigns, variously considering also other variables such as age, gender, vaccination settings, and possible vaccination campaigns. We also considered the reasons for low coverage and the approaches that might increase the vaccination rates. A lack of knowledge about the importance of vaccination in these patients and their doctors underlined the need to increase the awareness for vaccination in this patients’ category. Current guidelines recommend vaccination in elderly people and people affected by particular conditions that widely overlap with SSc, yet autoimmune diseases are not always clearly mentioned. Improving this suboptimal vaccination rate with clear guidelines is crucial for SSc patients and for clinicians to immunize these categories based principally on the pathology, prior to the age. Recommendations by the immunologist and the direct link to the vaccine providers can highly improve the vaccine coverage.
format	article
author	Francesca Rosamilia Giovanni Noberasco Dario Olobardi Andrea Orsi Giancarlo Icardi Francesca Lantieri Giuseppe Murdaca
author_facet	Francesca Rosamilia Giovanni Noberasco Dario Olobardi Andrea Orsi Giancarlo Icardi Francesca Lantieri Giuseppe Murdaca
author_sort	Francesca Rosamilia
title	Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review
title_short	Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review
title_full	Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review
title_fullStr	Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review
title_full_unstemmed	Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review
title_sort	flu and pneumococcal vaccine coverage in scleroderma patients still need to be prompted: a systematic review
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/e2670fc22abf44579f4378de197154a5
work_keys_str_mv	AT francescarosamilia fluandpneumococcalvaccinecoverageinsclerodermapatientsstillneedtobepromptedasystematicreview AT giovanninoberasco fluandpneumococcalvaccinecoverageinsclerodermapatientsstillneedtobepromptedasystematicreview AT darioolobardi fluandpneumococcalvaccinecoverageinsclerodermapatientsstillneedtobepromptedasystematicreview AT andreaorsi fluandpneumococcalvaccinecoverageinsclerodermapatientsstillneedtobepromptedasystematicreview AT giancarloicardi fluandpneumococcalvaccinecoverageinsclerodermapatientsstillneedtobepromptedasystematicreview AT francescalantieri fluandpneumococcalvaccinecoverageinsclerodermapatientsstillneedtobepromptedasystematicreview AT giuseppemurdaca fluandpneumococcalvaccinecoverageinsclerodermapatientsstillneedtobepromptedasystematicreview
_version_	1718410187481546752

Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review

Ejemplares similares